2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-115766S
    Anabaseine-d4 1020719-05-4 98%
    Anabaseine-d4 is the deuterium labeled Anabaseine (HY-115766). Anabaseine is a non-selective nicotinic agonist. Anabaseine stimulates all AChRs, preferentially stimulates skeletal muscle and brain α7 subtypes. Anabaseine is also a weak partial agonist at α4β2 nAChRs.
    Anabaseine-d4
  • HY-116016R
    Etilevodopa (Standard) 37178-37-3
    Chlorbenside (Standard) is the analytical standard of Chlorbenside. This product is intended for research and analytical applications. Chlorbenside is an organochlorine pesticide. Chlorbenside targets organism such as mites and ticks and possesses efficient ovicidal and larvicidal activities.
    Etilevodopa (Standard)
  • HY-116026R
    3-Hydroxycarbofuran (Standard) 16655-82-6
    3-Hydroxycarbofuran (Standard) is the analytical standard of 3-Hydroxycarbofuran. This product is intended for research and analytical applications. 3-Hydroxycarbofuran, a major metabolite of Carbofuran, is a reversible acetylcholinesterase (AChE) inhibitor.
    3-Hydroxycarbofuran (Standard)
  • HY-116062A
    JNJ-7925476 129540-12-1 98%
    JNJ-7925476 is a triple reuptake inhibitor that selectively and potently inhibits the activity of the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT). JNJ-7925476 is rapidly absorbed into the blood and its concentration in the brain is 7-fold higher than that in plasma. The occupancy ED(50) values of JNJ-7925476 for SERT, NET, and DAT in the rat brain are 0.18, 0.09, and 2.4 mg/kg, respectively. JNJ-7925476 rapidly induces a significant increase in the levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex in a dose-dependent manner. JNJ-7925476 exhibits potent antidepressant-like activity in the mouse tail suspension test. These results suggest that JNJ-7925476 has in vivo efficacy in biochemical and behavioral models of depression.
    JNJ-7925476
  • HY-116152A
    (S)-Cipepofol 1637741-59-3 98%
    (S)-Cipepofol is the isomer of Cipepofol (HY-116152).Cipepofol (HSK3486) is a sleep-promoting active molecule and a gamma-aminobutyric acid (GABA) receptor enhancer.
    (S)-Cipepofol
  • HY-116152S
    Cipepofol-d6 2677052-88-7 98%
    Cipepofol-d6 (Ciprofol-d6; HSK3486-d6) is deuterium labeled Cipepofol (HY-116152). Cipepofol (HSK3486), a psychomotor stabilizing agent, is a gamma-aminobutyric acid (GABA) receptor potentiator.
    Cipepofol-d6
  • HY-116392E
    D-threo-PDMP 109836-82-0 98%
    D-threo-PDMP is a potent glucoceramide synthase (GCS) inhibitor, which reduces the glycosphingolipids on the cell surface by inhibiting glycosylation, reduces the total length of the axon plexus and the number of axon branch points, and inhibits neurite growth.
    D-threo-PDMP
  • HY-116463A
    (2R,3S)-E1R 1424832-60-9 98.84%
    (2R,3S)-E1R (Compound 2c) is an enantiomer of E1R. (2R,3S)-E1R is a sigma-1 receptor positive allosteric modulator (Sig1R PAM) for the treatment of cognition/memory disorders.
    (2R,3S)-E1R
  • HY-116463B
    (2S,3S)-E1R 1424832-57-4 98.24%
    (2S,3S)-E1R (Compound 2d) is an enantiomer of E1R. (2S,3S)-E1R is a sigma-1 receptor positive allosteric modulator (Sig1R PAM) for the treatment of cognition/memory disorders.
    (2S,3S)-E1R
  • HY-116463C
    (2R,3R)-E1R 1400888-63-2 98.79%
    (2R,3R)-E1R (Compound 2b) is an enantiomer of E1R. (2R,3R)-E1R is a sigma-1 receptor positive allosteric modulator (Sig1R PAM) for the treatment of cognition/memory disorders.
    (2R,3R)-E1R
  • HY-116463D
    (Rac)-E1R 787623-60-3 98.48%
    (Rac)-E1R (Compound 2) is the racemate of E1R. (Rac)-E1R is a sigma-1 receptor positive allosteric modulator (Sig1R PAM) used for the research of cognition/memory disorders.
    (Rac)-E1R
  • HY-116535C
    D-threo-PPMP 139889-53-5 98%
    D-threo-PPMP is a potent inhibitor of glucosylceramide (GlcCer) synthase. D-threo-PPMP can block karyokinesis and reduce cyst production.
    D-threo-PPMP
  • HY-116586A
    (Rac)-AF710B 1235733-73-9 98%
    (Rac)-AF710B is the racemate of AF710B (HY-116586). AF710B is a highly potent and selective allosteric M1 muscarinic and σ1 receptor agonist. AF710B can be used for the research of Alzheimer’s disease.
    (Rac)-AF710B
  • HY-116780A
    Prothipendyl hydrochloride 1225-65-6 98%
    Prothipendyl hydrochloride is an orally active agent that can be used in the study of mental symptoms in the aged (e.g. anxiety).
    Prothipendyl hydrochloride
  • HY-116807R
    Dihydrolipoic Acid (Standard) 462-20-4
    Dihydrolipoic Acid (Standard) is the analytical standard of Dihydrolipoic Acid. This product is intended for research and analytical applications. Dihydrolipoic Acid (DHLA) is an excellent antioxidant capable of scavenging almost any oxygen-centered radical. Dihydrolipoic acid exhibits anti-inflammatory properties in various diseases. Dihydrolipoic Acid exerts a preventive effect via ERK/Nrf2/HO-1/ROS/NLRP3 pathway in LPS-induced sickness behavior rats. Dihydrolipoic Acid can be used for the reaserch of depression.
    Dihydrolipoic Acid (Standard)
  • HY-117046A
    AVN-101 hydrochloride 1061354-48-0 99.59%
    AVN-101 hydrochloride is a potent, brain-penetrant and orally active 5-HT7 receptor antagonist (Ki of 153 pM), with slightly lesser potency toward 5-HT6, 5-HT2A, and 5HT-2C receptors (Ki values of 2.04 nM, 1.56  nM, and 1.17  nM, respectively). AVN-101 hydrochloride also exhibits a rather high affinity toward histamine H1 (Ki of 0.58 nM) and adrenergic α2A, α2B, and α2C (Ki= 0.41-3.6 nM) receptors. AVN-101 hydrochloride can be studied in such diseases as general anxiety disorders, depression, schizophrenia, Alzheimer’s disease, and multiple sclerosis.
    AVN-101 hydrochloride
  • HY-117118A
    AC-90179 359878-19-6 98%
    AC-90179 is a selective 5-HT2A receptor inverse agonist (Ki = 2.1 nM) and 5-HT2C antagonist, a potential antipsychotic compound.
    AC-90179
  • HY-117216A
    L-703606 oxalate 351351-06-9 98%
    L-703606 oxalate is a potent, selective antagonist of NK1 receptor. L-703606 can be used for study of gastric acid secretion.
    L-703606 oxalate
  • HY-117275A
    Meclofenamic acid sodium hydrate 67254-91-5 98%
    Meclofenamic acid (Meclofenamate) sodium hydrate is a non-steroidal anti-inflammatory agent. Meclofenamic acid sodium hydrate is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid sodium hydrate competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid sodium hydrate is a non-selective gap-junction blocker. Meclofenamic acid sodium hydrate inhibits hKv2.1 and hKv1.1, with IC50 values of 56.0 and 155.9 μM, respectively.
    Meclofenamic acid sodium hydrate
  • HY-117275R
    Meclofenamic acid (Standard) 644-62-2
    Meclofenamic acid (Standard) is the analytical standard of Meclofenamic acid. This product is intended for research and analytical applications. Meclofenamic acid (Meclofenamate) is a non-steroidal anti-inflammatory agent. Meclofenamic acid is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker. Meclofenamic acid inhibits hKv2.1 and hKv1.1, with IC50 values of 56.0 and 155.9 μM, respectively.
    Meclofenamic acid (Standard)
Cat. No. Product Name / Synonyms Application Reactivity